AU2016268153B2 - Therapeutic uses of L-4-chlorokynurenine - Google Patents

Therapeutic uses of L-4-chlorokynurenine Download PDF

Info

Publication number
AU2016268153B2
AU2016268153B2 AU2016268153A AU2016268153A AU2016268153B2 AU 2016268153 B2 AU2016268153 B2 AU 2016268153B2 AU 2016268153 A AU2016268153 A AU 2016268153A AU 2016268153 A AU2016268153 A AU 2016268153A AU 2016268153 B2 AU2016268153 B2 AU 2016268153B2
Authority
AU
Australia
Prior art keywords
chlorokynurenine
depression
dose
tinnitus
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016268153A
Other languages
English (en)
Other versions
AU2016268153A1 (en
Inventor
Allen E Cato
Jack S Hicklin
H. Ralph Snodgrass
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vistagen Therapeutics Inc
Original Assignee
Vistagen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vistagen Therapeutics Inc filed Critical Vistagen Therapeutics Inc
Publication of AU2016268153A1 publication Critical patent/AU2016268153A1/en
Priority to AU2021209279A priority Critical patent/AU2021209279B2/en
Application granted granted Critical
Publication of AU2016268153B2 publication Critical patent/AU2016268153B2/en
Priority to AU2023282234A priority patent/AU2023282234A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016268153A 2015-05-22 2016-05-23 Therapeutic uses of L-4-chlorokynurenine Active AU2016268153B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021209279A AU2021209279B2 (en) 2015-05-22 2021-07-29 Therapeutic uses of L-4-chlorokynurenine
AU2023282234A AU2023282234A1 (en) 2015-05-22 2023-12-13 Therapeutic uses of L-4-chlorokynurenine

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562179924P 2015-05-22 2015-05-22
US62/179,924 2015-05-22
PCT/US2016/033733 WO2016191351A1 (en) 2015-05-22 2016-05-23 Therapeutic uses of l-4-chlorokynurenine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021209279A Division AU2021209279B2 (en) 2015-05-22 2021-07-29 Therapeutic uses of L-4-chlorokynurenine

Publications (2)

Publication Number Publication Date
AU2016268153A1 AU2016268153A1 (en) 2017-12-14
AU2016268153B2 true AU2016268153B2 (en) 2021-08-12

Family

ID=57393671

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016268153A Active AU2016268153B2 (en) 2015-05-22 2016-05-23 Therapeutic uses of L-4-chlorokynurenine
AU2021209279A Active AU2021209279B2 (en) 2015-05-22 2021-07-29 Therapeutic uses of L-4-chlorokynurenine
AU2023282234A Abandoned AU2023282234A1 (en) 2015-05-22 2023-12-13 Therapeutic uses of L-4-chlorokynurenine

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021209279A Active AU2021209279B2 (en) 2015-05-22 2021-07-29 Therapeutic uses of L-4-chlorokynurenine
AU2023282234A Abandoned AU2023282234A1 (en) 2015-05-22 2023-12-13 Therapeutic uses of L-4-chlorokynurenine

Country Status (19)

Country Link
US (3) US20180140568A1 (enExample)
EP (2) EP3297619B1 (enExample)
JP (3) JP2018521007A (enExample)
KR (2) KR20240068766A (enExample)
CN (1) CN107949379A (enExample)
AU (3) AU2016268153B2 (enExample)
BR (1) BR112017024908A2 (enExample)
CA (1) CA3024783A1 (enExample)
DK (1) DK3297619T3 (enExample)
EA (1) EA201792571A1 (enExample)
ES (1) ES2925274T3 (enExample)
IL (3) IL296380A (enExample)
MX (1) MX395492B (enExample)
PL (1) PL3297619T3 (enExample)
PT (1) PT3297619T (enExample)
SG (1) SG10202007661XA (enExample)
SI (1) SI3297619T1 (enExample)
WO (1) WO2016191351A1 (enExample)
ZA (1) ZA201707874B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3216579A1 (en) 2013-01-22 2014-07-31 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses of l-4-chlorokynurenine
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
KR20220045929A (ko) * 2019-04-09 2022-04-13 비스타젠 쎄라퓨틱스, 인크. 신경 질환의 치료 반응과 관련된 유전적 변이
IL299301A (en) * 2020-06-24 2023-02-01 Biohaven Therapeutics Ltd Compositions and methods for the treatment of obsessive compulsive disorder
WO2022221423A1 (en) * 2021-04-13 2022-10-20 Vistagen Therapeutics, Inc. Treatment of autoimmune anti-nmda-receptor encephalitis
CN115677519A (zh) * 2021-07-22 2023-02-03 立科时代(武汉)生物科技有限公司 L-4-溴-犬尿氨酸及其在制备治疗抑郁症药物中的应用
WO2024011105A1 (en) * 2022-07-05 2024-01-11 Mahana Therapeutics, Inc. Methods and systems for treating tinnitus using digital therapeutics

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014116739A1 (en) * 2013-01-22 2014-07-31 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses l-4-chlorokynurenine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484814A (en) 1991-02-28 1996-01-16 Merrell Dow Pharmaceuticals Inc. NMDA antagonists
EP1061924A1 (en) * 1998-03-09 2000-12-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
MXPA03005130A (es) * 2000-12-07 2004-12-06 Neuromolecular Inc Metodos para tratar trastornos neurosiquiatricos con antagonistas del receptor del nmda.
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
AU2007235876A1 (en) * 2006-04-12 2007-10-18 Probiodrug Ag Enzyme inhibitors
CA2606658A1 (en) * 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
KR20100100858A (ko) * 2007-11-06 2010-09-15 에모리 유니버시티 안전한 ｎｍｄａ 수용체 길항제의 식별 방법
TW201026667A (en) * 2008-09-30 2010-07-16 Merz Pharma Gmbh & Co Kgaa Glycine b antagonists
MX2015002378A (es) * 2012-08-23 2015-09-25 Stuart L Weg Composicion ansiolitica, formulacion y metodo de uso.
CN107417558A (zh) 2013-03-14 2017-12-01 维斯塔津治疗公司 用于合成手性犬尿氨酸化合物的方法
JP2016513718A (ja) 2013-03-14 2016-05-16 ヴィスタゲン セラピューティクス、インコーポレイテッド キラルキヌレニン化合物及び中間体の合成
BR112016025910A8 (pt) * 2014-05-06 2021-07-13 Univ Northwestern uso de uma quantidade eficaz de glyx-13, uso de glyx-13 e um antagonista de nmdar e composição farmaceuticamente aceitável compreendendo os mesmos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014116739A1 (en) * 2013-01-22 2014-07-31 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses l-4-chlorokynurenine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Guitton, MJ et al (2005) European Journal of Neuroscience 22: 2675-2678 *

Also Published As

Publication number Publication date
ES2925274T3 (es) 2022-10-14
CN107949379A (zh) 2018-04-20
US20190321317A1 (en) 2019-10-24
AU2016268153A1 (en) 2017-12-14
EP3297619A4 (en) 2019-01-02
EA201792571A1 (ru) 2018-06-29
SI3297619T1 (sl) 2023-02-28
US20180140568A1 (en) 2018-05-24
KR20240068766A (ko) 2024-05-17
DK3297619T3 (da) 2022-08-15
IL285882A (en) 2021-09-30
JP2022064908A (ja) 2022-04-26
JP2024050575A (ja) 2024-04-10
IL296380A (en) 2022-11-01
JP2018521007A (ja) 2018-08-02
IL255770A (en) 2018-01-31
WO2016191351A1 (en) 2016-12-01
EP3297619A1 (en) 2018-03-28
AU2021209279A1 (en) 2021-08-19
PL3297619T3 (pl) 2023-02-13
SG10202007661XA (en) 2020-09-29
ZA201707874B (en) 2020-01-29
HK1257800A1 (en) 2019-11-01
EP3297619B1 (en) 2022-07-06
EP4108239A1 (en) 2022-12-28
PT3297619T (pt) 2022-08-05
MX2017014456A (es) 2018-03-16
IL255770B (en) 2021-09-30
MX395492B (es) 2025-03-25
CA3024783A1 (en) 2016-12-01
KR20180015158A (ko) 2018-02-12
US20240122887A1 (en) 2024-04-18
AU2021209279B2 (en) 2023-09-14
AU2023282234A1 (en) 2024-01-18
BR112017024908A2 (pt) 2018-07-31

Similar Documents

Publication Publication Date Title
AU2021209279B2 (en) Therapeutic uses of L-4-chlorokynurenine
AU2022221382B2 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
WO2011011060A1 (en) Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
US20130281401A1 (en) Combination therapy for the treatment of depression and other non-infectious diseases
JP2008509147A (ja) ヒト神経精神病を治療するためのｎ−デスメチルクロザピンの使用
HK1257800B (en) Therapeutic uses of l-4-chlorokynurenine
HK40022228B (en) Dosage forms and therapeutic uses l-4- chlorokynurenine
HK40022228A (en) Dosage forms and therapeutic uses l-4- chlorokynurenine

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ SNODGRASS, H. RALPH; CATO, ALLEN E AND HICKLIN, JACK S

FGA Letters patent sealed or granted (standard patent)